



**OXIDE Corporation**  
**Supplementary Explanation Material for**  
**FY 2026 Feb 1Q Financial Results**

July 15, 2025 | TSE Growth: 6521

**Illuminate with Innovation - OXIDE**

Copyright: 2025 OXIDE Corporation. All Rights Reserved.

I will provide an explanation based on the supplementary explanatory materials for the financial results.

# Agenda

**OXIDE**

- 01.** Consolidated Financial Results for FY2026 Feb 1Q
- 02.** Results by Business Segment [Semiconductor, Healthcare, Frontier Tech.]
- 03.** Impact of Tariff Policies and Export Restrictions in the U.S. and China on Our Company (Updated 7/15)

FY2026 Feb 1Q Financial Highlights



- Revenue was generally in line with our budget, representing a significant increase year-on-year (YoY).
- Operating Profit improved significantly both compared to the budget and to the same period last year.  
Factors contributing to the increase include improved productivity, increased sales in Frontier Tech businesses, and changes in the product mix.

Revenue

JPY 1,787M

vs. Budget      ▲ JPY 26M  
YoY Change    + JPY 399M

Operating Profit

JPY 72M

vs. Budget      + JPY 142M  
YoY change    + JPY 334M

EBITDA Margin

8.6%

vs. Budget      + 8.3%  
YoY change    + 19.0%

First of all, I would like to explain the financial highlights for the first quarter of FY2026 Feb. Revenue for the period was generally in line with our budget and significantly higher than in the same period of the previous year. Operating Profit was significantly higher than both budget and year-on-year comparisons. Factors contributing to the increase include improved productivity, increased sales in Frontier Tech. businesses, and changes in the product mix.

# 01. Consolidated Results

## FY2026 Feb 1Q Results

OXIDE

- Revenue: JPY 1,787M (down JPY 26M from the budget; up JPY 399M from the previous year)
- Operating Loss: JPY 72M (an improvement of JPY 142M from the budget; an improvement of JPY 334M from the previous year)
- EBITDA: JPY 154M (up JPY 147M from the budget; up JPY 298M from the previous year)

(Unit : JPY M, %)

Item	FY26 Feb 1Q <sup>*1</sup>			(Reference) FY25 Feb 1Q	YoY change	FY26 Feb Full year
	Budget	Result	Variance			Budget
Revenue	1,814	1,787	▲ 26	1,388	+399	8,713
Operating Profit	▲ 215	▲ 72	+142	▲ 406	+334	409
(Operating Profit Margin)	▲11.9%	▲4.0%	+7.8	▲29.3%	+25.3%	4.7%
R&D Expenditure	337	465	+127	315	+150	1,330
EBITDA <sup>*2</sup>	6	154	+147	▲ 144	+298	1,278
(EBITDA margin ) <sup>*3</sup>	0.4%	8.6%	+8.3%	▲10.4%	+19.0%	14.7%

\*1 "FY26 Feb" denotes the fiscal year running from March 2025 to February 2026.

\*2 EBITDA: Operating Profit plus amortization (including depreciation, amortization of goodwill, etc.)

\*3 EBITDA Margin: EBITDA divided by Revenue

Copyright: 2025 OXIDE Corporation. All Rights Reserved.

4

I would like to explain the results for the first quarter of FY2026 Feb.

Revenue was JPY 1,787M. This is a JPY 26M decrease from the budget and a JPY 399M increase from the same period last year.

Operating loss was JPY 72M. This is an increase of JPY 142M from the budget, and an increase of JPY 334M from the same period last year.

EBITDA was JPY 154M. This is an increase of JPY 147M over the budget, and an increase of JPY 298M over the same period last year.



02. Results by Business Segment

Semiconductor | Revenue

OXIDE

- Revenue from Semiconductor business was JPY 834M.
- Revenue increased by JPY 235M from the same period of the previous year.

Item	FY26 Feb 1Q			(Reference) FY25 Feb 1Q	YoY change	(Unit:JPY M)
	Budget	Result	Variance			FY26 Feb Full year Budget
Revenue	890	834	▲ 55	599	+ 235	4,555



I would like to explain our business performance by segment.

Revenue from the Semiconductor business was JPY 834M.

Revenue decreased by JPY 55M compared to the budget, but increased by JPY 235M compared to the same period last year.



02. Results by Business Segment

Healthcare | Revenue

OXIDE

- Revenue from Healthcare business was JPY 346M.
- Shipments to a new customer, a leading manufacturer of high-performance PET equipment, drove a revenue increase of JPY 117M year-on-year.

Item	FY26 Feb 1Q			(Reference) FY25 Feb 1Q	YoY change	(Unit:JPY M)
	Budget	Result	Variance			FY26 Feb Full year Budget
Revenue	401	346	▲ 55	229	+ 117	2,170



I will now explain our Healthcare business.

Revenue from the Healthcare business was JPY 346M.

Although Revenue was JPY 55M below budget, shipments to a new customer, a leading manufacturer of high-performance PET, contributed to a year-on-year increase of JPY 117M in Revenue.


02. Results by Business Segment

Frontier Tech | Revenue

OXIDE

- Revenue from Frontier Tech business amounted to JPY 606M.
- Sales increased by JPY 47M from the same period of the previous fiscal year due to contributions from projects for data centers.

Item	FY26 Feb 1Q			(Reference) FY25 Feb 1Q	YoY change	(Unit:JPY M)
	Budget	Result	Variance			FY26 Feb Full year Budget
Revenue	521	606	+ 84	559	+ 47	1,987



Markets where commercialization is progressing

Aerospace & Defense

Advanced Optical Measurement

Medical Aesthetics

Optical Components

Markets with medium- to long-term growth potential

Power Semiconductors

Quantum

Data center

Smart grid

I will now explain our Frontier Tech business.

Revenue from the Frontier Tech business amounted to JPY 606M.

Revenue increased by JPY 84M compared to the budget, and by JPY 47M year-on-year, due to the contribution of projects for data centers, etc.

## Frontier Tech | The Situation in Israel and Raicol's Current Status

OXIDE


### Current Status

- At this time, there is no direct damage to Raicol's buildings, manufacturing equipment, or research and development equipment.
- Following the ceasefire on June 25, employees have returned to office operations and have resumed business activities. In addition, about 10 employees were called to reserve duty, but are now gradually returning to work.
- The airport is operating normally, and international logistics has also resumed.

### Outlook

- Revenue is expected to be conservative, and at this point, we do not anticipate any significant impact on our earnings forecast disclosed in April 2025.
- We will continue to monitor the situation closely.

Location of Raicol\*1



(■: Palestinian territories (West Bank and Gaza Strip))

Copyright: 2025 OXIDE Corporation. All Rights Reserved. \*1 Map is taken from the website of the Ministry of Foreign Affairs of Japan.

8

The following is an update on the situation in Israel and Raicol's current status.

At this time, there is no direct damage to Raicol's buildings, manufacturing equipment, or R&D equipment.

Following the ceasefire on June 25, employees have returned to office operations and have resumed business activities.

In addition, about 10 employees were called to reserve duty, but are now gradually returning to work.

The airport is operating normally, and international logistics has also resumed.

Revenue is conservatively estimated, and at this point, we do not anticipate any significant impact on our budget disclosed in April 2025.

We will continue to monitor the situation closely.



06. Impact of Tariff Policies and Export Controls by the U.S. and China

Impact of Tariff Policies and Export Controls by the U.S. and China (Updated 7/15)**OXIDE**

■ ■ We have updated the impact of tariff policies and export controls in the U.S. and China on our company as of July 15, 2025, which was previously disclosed in April 2025.

	Semiconductor	Healthcare	Frontier Tech
Our production sites	Japan	Japan	Japan and Israel
U.S. Policy Effects	<p>[Risk] We believe that the impact of the U.S. tariff policy will be limited due to our low dependence on U.S. shipments of laser products.</p> <p>The market share of wavelength conversion single crystals is over 95%, and we believe that replacement with other companies' products will be difficult in terms of quality and production system, and that the impact of the U.S. tariff policy will be limited. <b>(Updated 7/15)</b> <b>We believe that the impact of the 25% tariff will be negligible.</b></p> <p>[Business Opportunity] U.S. export controls may limit purchases of U.S. products by Chinese Semiconductor equipment manufacturers. Therefore, inquiries to our company are increasing. <b>(Updated 7/15)</b> <b>Inquiries are increasing rapidly.</b></p>	<p>[Risk] The degree of impact of the U.S. tariff policy is currently under scrutiny. <b>(Updated 7/15)</b> <b>Some products were found to be exempt from tariffs and the impact on business is expected to be negligible.</b></p> <p>[Business Opportunity] Even if not affected by Chinese export controls, U.S. crystal manufacturers may see their business development affected by the U.S. tariff policy. Therefore, inquiries to our company may increase.</p>	<p>[Risk] We believe that the impact of the U.S. tariff policy will be limited due to the low dependence on U.S. shipments of Frontier Tech business products.</p> <p>The impact of the U.S. tariff policy on Raicol's products is expected to be limited, as tariffs on Israeli products are lower than those in other major countries.</p> <p>[Business Opportunity] U.S. customers may be reluctant to purchase Chinese products due to the U.S. tariff policy and long-term procurement concerns. As a result, the number of inquiries to us and Raicol may increase.</p>

We would like to explain the impact of U.S. and Chinese tariff policies and export regulations on our company. This is an update to the information disclosed in April of this year, reflecting the latest developments as of July 15.

First, regarding risks in the semiconductor business, we believe the impact of the 25% tariff announced by the U.S. government this month is minimal.

In terms of business opportunities, we are seeing a sharp increase in inquiries from Chinese customers.

Next, regarding risks in the healthcare business, we have confirmed that some products are exempt from tariffs, and we believe the impact on our business is also minimal.

We will continue to closely monitor developments in tariff policies and export regulations, and proactively pursue business opportunities.

06. Impact of Tariff Policies and Export Controls by the U.S. and China

Impact of Tariff Policies and Export Controls by the U.S. and China (Updated 7/15)





	Semiconductor	Healthcare	Frontier Tech
Our production sites	Japan	Japan	Japan and Israel
China Policy Effects	<p>[Business Opportunity] China's tariff policy may affect Chinese Semiconductor equipment manufacturers when they purchase products from the United States. Therefore, inquiries to our company are increasing.</p>	<p>[Risk] We are currently examining the degree of impact of China's export controls.</p> <p>[Business Opportunity] China's export controls may limit the purchase of Chinese raw materials by U.S. crystal manufacturers. This may lead to an increase in inquiries to our company.</p>	<p>[Business Opportunities] Prices of laser products, which are not affected by U.S. export controls, may rise due to China's tariff policy. For this reason, inquiries to our company are increasing.</p>

# Appendix

Financial Trends

OXIDE



\*The allocation of the acquisition cost was revised in FY2024 Feb due to the finalization of the PPA for the acquisition of Raicol as a subsidiary. As a result, the figures for the second and third quarters of FY2024 Feb. have been retroactively adjusted.

# OXIDE

## DISCLAIMER

This material was not prepared for the purpose of soliciting investments in securities issued by the Company.

The information contained in this material is based on our assumptions and beliefs at the time of preparation and we do not guarantee or promise the accuracy or completeness of such information.

The report contains risks, economic trends, industry demand, and other uncertainties that may affect actual results.

Our estimates and actual results may differ. Please be aware that actual results may differ from our projections.

Amounts in this document are rounded down to the indicated unit, and percentages are rounded off to the indicated unit, so the total of the breakdown may not equal the total.

In the fourth quarter of FY2024 Feb, the allocation of the acquisition cost was revised due to the finalization of the PPA for the acquisition of Raicol as a subsidiary. As a result, the figures for the second and third quarters of FY2024 Feb. have been retroactively adjusted.

Illuminate with Innovation - OXIDE

<https://www.opt-oxide.com>

Copyright: 2025 OXIDE Corporation. All Rights Reserved.